In 34 adults aged ≥65 with type 1 diabetes (29 completed), the MiniMed 780G advanced hybrid closed-loop raised time in range vs injections or pump over 12 months (adjusted difference 15.7%) and lowered HbA1c (−5 mmol/mol), with no severe hypoglycaemia.
RCTn = 34
Matejko et al. Metabolic and vascular outcomes after transition to the MiniMed 780G system in adults ≥65 years with type 1 diabetes: a randomised, single-centre study